In autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), CAR-T cells targeting B-cell antigens such as CD19 or BCMA have achieved significant, drug-free remissions by removing autoreactive B cells and reestablishing immune tolerance. This evidence concerns the gene CD19 and rheumatoid arthritis.